Imaging and Management of Postprandial Abdominal Pain in Immunosuppressed Patients

Immediate Diagnostic Imaging

In immunosuppressed patients presenting with post‑prandial abdominal pain, obtain an immediate contrast‑enhanced CT of the abdomen and pelvis to rule out life‑threatening infectious colitis (CMV, C. difficile) or neutropenic enterocolitis; delayed diagnosis is associated with mortality rates of 35‑70%【1】【2】.
Contrast‑enhanced CT is the gold‑standard imaging modality for this population, providing superior diagnostic yield compared with plain radiography【3】.
A single‑phase CT with intravenous contrast alone is sufficient; routine oral contrast adds delay without diagnostic benefit【3】.
Plain abdominal radiographs are frequently nondiagnostic, showing normal findings in up to 68 % of C. difficile colitis cases【1】【4】.

Bowel wall thickening is almost universally present on CT【1】.
Small‑bowel involvement occurs in up to 40 % of cases and helps differentiate CMV from C. difficile colitis【1】.
Pancolitis is rare in CMV infection, unlike C. difficile colitis【1】.

Colonic wall thickening is identified in 84 % of patients on CT【6】.
Pancolitis is seen in approximately 50 % of cases【1】.
Free intra‑abdominal fluid is present in 77 % of patients on ultrasound, supporting the diagnosis【5】.

Wall thickening of the cecum and proximal ascending colon is characteristic, and this entity accounts for the most frequent cause of abdominal pain in neutropenic patients (28 %)【3】.

Solid‑organ transplant recipients: C. difficile incidence ranges 0.77‑11.3 % (kidney), 0.63‑19 % (liver), and 1.93‑22.9 % (lung)【5】; most infections occur within the first month post‑transplant【5】.
Hematology‑oncology patients: C. difficile infection rates vary from 6‑33 %【4】; additional risk factors include grade ≥ 2 mucositis, high‑dose chemotherapy, and CMV reactivation【5】.
People living with HIV: incidence of C. difficile infection is 7.1‑8.3 per 1,000 patients per year, with CD4 counts ≤ 50 cells/µL markedly increasing risk【5】.

First‑line therapy is intravenous ganciclovir 5 mg/kg administered twice daily in adults【1】.
After 3‑5 days, switch to oral valganciclovir 900 mg twice daily to complete a 2‑3‑week course【8】.
Pediatric patients require 14‑21 days of parenteral ganciclovir; early oral transition may precipitate viral reactivation【8】.
Broad‑spectrum antibiotics should be added to cover possible bacterial superinfection【1】.

Initiate disease‑specific medical therapy without delay【9】.
Early surgical consultation is advised for severe disease with systemic toxicity【4】.

Subtotal or partial colectomy is indicated for toxic megacolon, fulminant colitis, perforation, or ischemia【1】.
In‑hospital mortality approaches 70 % among severely ill patients despite optimal therapy【2】【9】.
Mortality rises seven‑fold when CMV colitis co‑exists with inflammatory bowel disease【1】【4】.

Emergent subtotal colectomy is the preferred operative strategy, offering superior outcomes to segmental resection【1】.
A diverting loop ileostomy combined with antegrade colonic vancomycin lavage provides an effective colon‑preserving alternative【9】.
Emergency surgery carries a mortality rate of approximately 35 %【5】【8】.

CMV‑specific immunohistochemistry on colonic biopsies is the gold‑standard diagnostic test for CMV colitis【7】.
“Owl‑eye” nuclear inclusions on hematoxylin‑eosin staining are highly specific for CMV infection【1】.
Punched‑out ulcerations are observed in up to 80 % of CMV colitis cases【6】.
A characteristic ulcer involving the cecum and ileocecal valve may suggest graft‑versus‑host disease in transplant recipients【2】.

Do not postpone contrast‑enhanced CT in favor of plain radiographs; immediate CT improves diagnostic timeliness【3】.
Prompt surgical consultation is essential; delayed operative intervention is the most significant factor worsening survival in severe C. difficile colitis【5】.
Blood CMV serology lacks diagnostic utility because > 70 % of adults are seropositive【6】.